Related Experiment Video
Updated: Jul 15, 2025

Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
Rituximab and improved nodular regenerative hyperplasia-associated non-cirrhotic liver disease in common variable
Willem Roosens1, Frederik Staels1, Sien Van Loo2
1Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.
Abstract:
Common variable immunodeficiency (CVID) associated liver disease is an underrecognized and poorly studied non-infectious complication that lacks an established treatment. We describe a CVID patient with severe multiorgan complications, including non-cirrhotic portal hypertension secondary to nodular regenerative hyperplasia leading to diuretic-refractory ascites. Remarkably, treatment with rituximab, administered for concomitant immune thrombocytopenia, resulted in the complete and sustained resolution of portal hypertension and ascites. Our case, complemented with a literature review, suggests a beneficial effect of rituximab that warrants further research.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Nephrotic Syndrome II : Assessment and Medical Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
Nephrotic Syndrome I : Introduction

